SOURCE: Xtalks

Xtalks Webinars

March 11, 2015 07:05 ET

Emerging Role of Biomarkers in Improving the Success Rate of Early Oncology Drug Development, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - March 11, 2015) - This webinar is intended to help Oncology drug developers explore Biomarkers in the design of clinical trials. The complimentary 90-minute broadcast takes place on Tuesday, March 31, 2015 at 11am EDT / 4pm BST (UK GMT +1).

Many new anticancer drugs target proteins encoded by genes with driver somatic mutations, thus exhibiting efficacy only in a subgroup of patients whose tumors harbor these mutations like KRAS/EGFR and EML4-ALK mutations in NSCLC. This has resulted in changes to standard clinical trial design to include a study population with patients whose tumors carry a particular mutation, set of mutations, or other biomarkers, increasing the potential of response to targeted therapy. Quest Diagnostics will discuss current mutation testing guidelines and best practices for patients with NSCLC, compares and contrasts anaplastic lymphoma kinase (ALK) testing methodologies and discusses the advantages offered by FISH for ALK mutation status testing.

Next-generation sequencing (NGS) has numerous roles in oncology clinical trials from identification of genomic biomarkers for response and/or primary resistance and patient eligibility by diagnostic panels that aid in confirmatory diagnosis. In an unsuccessful clinical trial, NGS data can be assessed to explain unexpected clinical trial outcomes, providing insight into the mechanism of drug effect and possible reasons for intergroup differences in response rate.

One of the latest NGS applications is a patient stratification tool for AML clinical trial programs implementing new molecular markers into the diagnostic algorithms for myeloid neoplasms. This illustrates the principle of innovative molecular monitoring following treatment of AML.

The panel of speakers include Dr. Kamala Maddali, Director of Scientific Development at Quest Diagnostics Clinical Trials, Dr. Arturo Anguiano, International Medical Director -- Medical Affairs at Quest Diagnostics, and Dr. Frederick Racke, Medical Director, Hematopathology and Coagulation, at Quest Diagnostics Nichols Institute for an informative session. Quest Diagnostics uses next-generation sequencing technologies to develop and offer molecular biomarkers as laboratory-developed tests for clinical trials to mitigate clinical drug development risks thereby improving your company's probability of successfully developing new oncology treatments.

To learn more about this event visit: Emerging Role of Biomarkers in Improving the Success Rate of Early Oncology Drug Development

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2015/3/10/11G035298/Images/Quest_Diagnostics_logo_green-701421402610.gif

Contact Information